PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway
[Display omitted] Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 co...
Saved in:
Published in | Biochemical pharmacology Vol. 225; p. 116314 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Inc
01.07.2024
|
Subjects | |
Online Access | Get full text |
ISSN | 0006-2952 1873-2968 1873-2968 |
DOI | 10.1016/j.bcp.2024.116314 |
Cover
Abstract | [Display omitted]
Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis. |
---|---|
AbstractList | Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis.Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis. [Display omitted] Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE-/- mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis. Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant role in the development of atherosclerosis. In this chronic inflammatory environment, we aimed to investigate whether PCSK9 could mitigate atherosclerosis progression by reducing tissue factor expression in ECs via in vivo and in vitro assays. In vivo, we investigated the effect of PCSK9 inhibition on preventing atherosclerotic lesion formation in ApoE mice fed a western diet. The results showed that inhibiting PCSK9 could significantly downregulate the protein expression of tissue factor (TF) in ECs to reduce the area of atherosclerotic plaques. In vitro, we incubated human umbilical vein endothelial cells (HUVECs) with lipopolysaccharide (LPS). We found that LPS-induced TF elevation was suppressed by a PCSK9 inhibitor at both the mRNA and protein levels and that the TLR4/NF-κB pathway was also suppressed by a PCSK9 inhibitor. With respect to plasma samples from patients with carotid artery stenosis, we also demonstrated that the expression of TF was positively correlated with that of PCSK9. Thus, in addition to regulating lipid metabolism, the regulation of endothelial cell TF expression through the TLR4/NF-κB pathway may be a potential mechanism of PCSK9 in promoting atherosclerotic carotid stenosis. |
ArticleNumber | 116314 |
Author | Yang, Xin-yu Jiang, Yu-hang Zhang, Heng-rui Li, Tian-xing Peng, Chao Chen, Yan Zhao, Yan Li, Jian |
Author_xml | – sequence: 1 givenname: Chao surname: Peng fullname: Peng, Chao email: pengchao3892@163.com – sequence: 2 givenname: Jian surname: Li fullname: Li, Jian email: lijian1011s@tmu.edu.cn – sequence: 3 givenname: Yan surname: Chen fullname: Chen, Yan email: chenyan19998@163.com – sequence: 4 givenname: Heng-rui surname: Zhang fullname: Zhang, Heng-rui email: zhanghengrui@tmu.edu.cn – sequence: 5 givenname: Tian-xing surname: Li fullname: Li, Tian-xing email: ltxsmm@163.com – sequence: 6 givenname: Yu-hang surname: Jiang fullname: Jiang, Yu-hang email: jiangbao@tmu.edu.cn – sequence: 7 givenname: Xin-yu surname: Yang fullname: Yang, Xin-yu email: yangxinyu@tmu.edu.cn – sequence: 8 givenname: Yan surname: Zhao fullname: Zhao, Yan email: tjmuzhaoyan@163.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38797271$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUFuEzEUhi1URNPCAdggL9lMYnsmHlusStRSRAQIytp6Y79JHU3Gg-0EchLu0kNwJiZNYcGiK9vS9z09__8ZOelDj4S85GzKGZez9bSxw1QwUU05lyWvnpAJV3VZCC3VCZkwxuR4n4tTcpbS-vBUkj8jp6WqdS1qPiG_Pi--ftAUVqsIO8joqIUYsncUYsa4pyljH5JP1Pf0YgiXxaygG2-RNns6xLAZ2X5F8y1S_DlETMmHnoaWZp_SFmkLNod4b2Pvwsh1HjpqsesS3Xm4N2-WX6rZx6vi991bOkC-_QH75-RpC13CFw_nOfl2dXmzuC6Wn969X1wsCyukyoVlcwZC1rKtGye0blWJNei50lIKlK5sSqVBtQ0D69pStMohCK6d5bwSjpXn5PVx7viX71tM2Wx8OmwHPYZtMiWTrJ6LSukRffWAbpsNOjNEv4G4N3_DHAF-BGwMKUVs_yGcmUNhZm3GwsyhMHMsbHTq_xzrM-QxxBzBd4-ab44mjvHsPEaTrMfeovMRbTYu-EfsPxfhsKM |
CitedBy_id | crossref_primary_10_1016_j_athplu_2024_12_004 crossref_primary_10_1111_apha_14272 crossref_primary_10_1016_j_metabol_2024_156064 |
Cites_doi | 10.1001/jamanetworkopen.2019.11130 10.1172/JCI122440 10.1161/CIRCRESAHA.115.306301 10.3389/fimmu.2022.894789 10.1016/S1474-4422(21)00359-8 10.1038/s41569-019-0239-5 10.1161/CIRCULATIONAHA.105.567297 10.1093/cvr/cvz313 10.1160/TH14-05-0451 10.7150/thno.83914 10.3390/ijms20020405 10.1016/j.yjmcc.2018.11.018 10.1161/01.CIR.101.22.2651 10.1161/ATVBAHA.117.309846 10.1007/s11239-011-0585-6 10.3390/ijms222312640 10.1016/j.bbrc.2008.07.023 10.1161/01.CIR.91.3.619 10.3389/fcvm.2022.888390 10.1038/s41574-018-0110-5 10.1016/j.ejphar.2020.173422 10.1161/CIRCULATIONAHA.120.046290 10.1016/j.thromres.2012.06.007 10.1124/pharmrev.120.000096 10.1016/j.intimp.2023.111195 10.1210/endrev/bnab035 10.1161/CIRCULATIONAHA.121.056491 10.1016/j.atherosclerosis.2017.04.023 10.1161/01.CIR.0000015465.73933.3B 10.1161/JAHA.121.023328 |
ContentType | Journal Article |
Copyright | 2024 Elsevier Inc. Copyright © 2024 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2024 Elsevier Inc. – notice: Copyright © 2024 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.bcp.2024.116314 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2968 |
ExternalDocumentID | 38797271 10_1016_j_bcp_2024_116314 S0006295224002971 |
Genre | Journal Article |
GroupedDBID | --- --K --M -~X .55 .GJ .HR .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXUO AAYJJ ABFNM ABFRF ABJNI ABLJU ABMAC ABWVN ABXDB ABZDS ACDAQ ACGFO ACGFS ACIUM ACNCT ACRLP ACRPL ADBBV ADEZE ADMUD ADNMO AEBSH AEFWE AEKER AENEX AFFNX AFJKZ AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AI. AIEXJ AIKHN AITUG AJOXV AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LPU M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI TWZ VH1 WH7 WUQ X7M ZGI ZXP ~G- AATTM AAYWO AAYXX ACVFH ADCNI AEIPS AEUPX AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EFKBS EIF NPM 7X8 EFLBG |
ID | FETCH-LOGICAL-c268t-c050a2676f7bd299f83e7a9589662e6d3b389a8fb0acdf32f8dea219dc1142d03 |
IEDL.DBID | AIKHN |
ISSN | 0006-2952 1873-2968 |
IngestDate | Fri Sep 05 00:43:55 EDT 2025 Mon Jul 21 06:05:59 EDT 2025 Tue Jul 01 02:23:49 EDT 2025 Thu Apr 24 23:01:06 EDT 2025 Sat Dec 21 15:59:43 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | LDL-C Tissue factor PCSK9 Proprotein convertase subtilisin/kexin type 9 LPS Endothelial cells TF ECs CAS ND Atherosclerosis PL Carotid artery stenosis HUVECs CID |
Language | English |
License | Copyright © 2024 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c268t-c050a2676f7bd299f83e7a9589662e6d3b389a8fb0acdf32f8dea219dc1142d03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 38797271 |
PQID | 3060752489 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3060752489 pubmed_primary_38797271 crossref_primary_10_1016_j_bcp_2024_116314 crossref_citationtrail_10_1016_j_bcp_2024_116314 elsevier_sciencedirect_doi_10_1016_j_bcp_2024_116314 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | July 2024 2024-07-00 2024-Jul 20240701 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: July 2024 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Biochemical pharmacology |
PublicationTitleAlternate | Biochem Pharmacol |
PublicationYear | 2024 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Li, He, Lv, Liu, Lv, Zhang, Zhu, Ai (b0090) 2019; 129 Bonati, Jansen, de Borst, Brown (b0005) 2022; 21 Gimbrone, Garcia-Cardena (b0120) 2016; 118 Wang, Li, Zhao, Liu, Tan, Xing, Adi, Wang, Fu, Ma, Liu, Liu, Wang, Shi, Lu, Song, Luo (b0100) 2022; 145 Steffel, Luscher, Tanner (b0025) 2006; 113 Zheng, Zhu, Li, Xu, Zhang (b0105) 2024; 126 Lee, Park, Hwang, Lee, Park, Kang, Lee, Kim, Park, Park (b0030) 2011; 32 Eto, Kozai, Cosentino, Joch, Luscher (b0150) 2002; 105 Cirillo, Ziviello, Pellegrino, Conte, Cimmino, Giaquinto, Pacifico, Leonardi, Golino, Trimarco (b0045) 2015; 113 Seidah, Prat (b0065) 2022; 43 Liu, Ma, Ma, Liu, Zhang, Zhang, Ni (b0140) 2019; 127 Grover, Mackman (b0020) 2018; 38 Stoekenbroek, Lambert, Cariou, Hovingh (b0055) 2018; 15 Souilhol, Serbanovic-Canic, Fragiadaki, Chico, Ridger, Roddie, Evans (b0015) 2020; 17 Annex, Denning, Channon, Sketch, Stack, Morrissey, Peters (b0035) 1995; 91 Cirillo, Di Palma, Maresca, Pacifico, Ziviello, Bevilacqua, Trimarco, Leonardi, Chiariello (b0145) 2012; 130 Hasenstab, Lea, Hart, Lok, Clowes (b0050) 2000; 101 Hao, Pang, Du, Lai, Chen, Xie, Zhou, Hou, Hsiao, Deng (b0155) 2019; 20 Liu, Wu, Stolarz, Zhang, Boerma, Byrum, Rusch, Ding (b0070) 2023; 13 Howe, Cybulsky, Fish (b0115) 2022; 9 Cimmino, Morello, Conte, Pellegrino, Marra, Golino, Cirillo (b0040) 2020; 885 Ding, Pothineni, Goel, Luscher, Mehta (b0080) 2020; 116 Feingold, Moser, Shigenaga, Patzek, Grunfeld (b0130) 2008; 374 Xu, Ilyas, Little, Li, Kamato, Zheng, Luo, Li, Liu, Han, Harding, Ebong, Cameron, Stewart, Weng (b0010) 2021; 73 Scalise, Sanguinetti, Neri, Cianchetti, Lai, Carnicelli, Celi, Pedrinelli (b0110) 2021; 22 Zou, Chen, Zhang, Yu, Xu, Cui, Li, Niu, Zhou, Xia, Wu (b0095) 2022; 13 Qi, Hu, Zhang, Yang, Liu, Jia, Yao, Chang, Pan, Zhong, Luo, Yao, Sun, Qian, Ding, Ge (b0060) 2021; 143 Punch, Klein, Diaba-Nuhoho, Morawietz, Garelnabi (b0125) 2022; 11 Wang, Li, Guo, Chen, Jiang, Song (b0135) 2016; 13 Feng, Wei, Chaugai, Carranza Leon, Kawai, Carranza Leon, Jiang, Zhong, Liu, Ihegword, Shaffer, Linton, Chung, Stein (b0075) 2019; 2 Tang, Peng, Ren, Yang, Li, Li, Wang, Wei, Liu, Zheng, Jiang (b0085) 2017; 262 Grover (10.1016/j.bcp.2024.116314_b0020) 2018; 38 Stoekenbroek (10.1016/j.bcp.2024.116314_b0055) 2018; 15 Zheng (10.1016/j.bcp.2024.116314_b0105) 2024; 126 Cirillo (10.1016/j.bcp.2024.116314_b0045) 2015; 113 Ding (10.1016/j.bcp.2024.116314_b0080) 2020; 116 Cirillo (10.1016/j.bcp.2024.116314_b0145) 2012; 130 Liu (10.1016/j.bcp.2024.116314_b0070) 2023; 13 Cimmino (10.1016/j.bcp.2024.116314_b0040) 2020; 885 Feng (10.1016/j.bcp.2024.116314_b0075) 2019; 2 Xu (10.1016/j.bcp.2024.116314_b0010) 2021; 73 Bonati (10.1016/j.bcp.2024.116314_b0005) 2022; 21 Howe (10.1016/j.bcp.2024.116314_b0115) 2022; 9 Lee (10.1016/j.bcp.2024.116314_b0030) 2011; 32 Hao (10.1016/j.bcp.2024.116314_b0155) 2019; 20 Annex (10.1016/j.bcp.2024.116314_b0035) 1995; 91 Seidah (10.1016/j.bcp.2024.116314_b0065) 2022; 43 Zou (10.1016/j.bcp.2024.116314_b0095) 2022; 13 Wang (10.1016/j.bcp.2024.116314_b0135) 2016; 13 Gimbrone (10.1016/j.bcp.2024.116314_b0120) 2016; 118 Qi (10.1016/j.bcp.2024.116314_b0060) 2021; 143 Punch (10.1016/j.bcp.2024.116314_b0125) 2022; 11 Liu (10.1016/j.bcp.2024.116314_b0140) 2019; 127 Souilhol (10.1016/j.bcp.2024.116314_b0015) 2020; 17 Tang (10.1016/j.bcp.2024.116314_b0085) 2017; 262 Hasenstab (10.1016/j.bcp.2024.116314_b0050) 2000; 101 Eto (10.1016/j.bcp.2024.116314_b0150) 2002; 105 Steffel (10.1016/j.bcp.2024.116314_b0025) 2006; 113 Feingold (10.1016/j.bcp.2024.116314_b0130) 2008; 374 Wang (10.1016/j.bcp.2024.116314_b0100) 2022; 145 Li (10.1016/j.bcp.2024.116314_b0090) 2019; 129 Scalise (10.1016/j.bcp.2024.116314_b0110) 2021; 22 |
References_xml | – volume: 43 start-page: 558 year: 2022 end-page: 582 ident: b0065 article-title: The Multifaceted Biology of PCSK9 publication-title: Endocr. Rev. – volume: 129 start-page: 1167 year: 2019 end-page: 1179 ident: b0090 article-title: c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow publication-title: J. Clin. Invest. – volume: 126 year: 2024 ident: b0105 article-title: PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway publication-title: Int. Immunopharmacol. – volume: 11 start-page: e023328 year: 2022 ident: b0125 article-title: Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis publication-title: J. Am. Heart Assoc. – volume: 885 year: 2020 ident: b0040 article-title: Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-kappaB pathway publication-title: Eur. J. Pharmacol. – volume: 2 start-page: e1911130 year: 2019 ident: b0075 article-title: A genetic approach to the association between PCSK9 and sepsis publication-title: JAMA Netw. Open – volume: 262 start-page: 113 year: 2017 end-page: 122 ident: b0085 article-title: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway publication-title: Atherosclerosis – volume: 21 start-page: 273 year: 2022 end-page: 283 ident: b0005 article-title: Management of atherosclerotic extracranial carotid artery stenosis publication-title: Lancet Neurol. – volume: 20 year: 2019 ident: b0155 article-title: Peach kernel oil downregulates expression of tissue factor and reduces atherosclerosis in ApoE knockout Mice publication-title: Int. J. Mol. Sci. – volume: 145 start-page: 675 year: 2022 end-page: 687 ident: b0100 article-title: Ablation of plasma prekallikrein decreases low-density lipoprotein cholesterol by stabilizing low-density lipoprotein receptor and protects against atherosclerosis publication-title: Circulation – volume: 13 start-page: 2914 year: 2023 end-page: 2929 ident: b0070 article-title: PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging publication-title: Theranostics – volume: 13 start-page: 312 year: 2016 end-page: 315 ident: b0135 article-title: Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus publication-title: J. Geriatr. Cardiol. – volume: 101 start-page: 2651 year: 2000 end-page: 2657 ident: b0050 article-title: Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis publication-title: Circulation – volume: 105 start-page: 1756 year: 2002 end-page: 1759 ident: b0150 article-title: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways publication-title: Circulation – volume: 17 start-page: 52 year: 2020 end-page: 63 ident: b0015 article-title: Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes publication-title: Nat. Rev. Cardiol. – volume: 15 start-page: 52 year: 2018 end-page: 62 ident: b0055 article-title: Inhibiting PCSK9 - biology beyond LDL control publication-title: Nat. Rev. Endocrinol. – volume: 116 start-page: 908 year: 2020 end-page: 915 ident: b0080 article-title: PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1 publication-title: Cardiovasc. Res. – volume: 113 start-page: 363 year: 2015 end-page: 372 ident: b0045 article-title: The adipokine apelin-13 induces expression of prothrombotic tissue factor publication-title: Thromb. Haemost. – volume: 38 start-page: 709 year: 2018 end-page: 725 ident: b0020 article-title: Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis publication-title: Arterioscler. Thromb. Vasc. Biol. – volume: 113 start-page: 722 year: 2006 end-page: 731 ident: b0025 article-title: Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications publication-title: Circulation – volume: 9 year: 2022 ident: b0115 article-title: The endothelium as a hub for cellular communication in atherogenesis: is there directionality to the message? publication-title: Front Cardiovasc Med – volume: 13 year: 2022 ident: b0095 article-title: Targeting PCSK9 ameliorates graft vascular disease in mice by inhibiting NLRP3 inflammasome activation in vascular smooth muscle cells publication-title: Front. Immunol. – volume: 91 start-page: 619 year: 1995 end-page: 622 ident: b0035 article-title: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes publication-title: Circulation – volume: 127 start-page: 1 year: 2019 end-page: 10 ident: b0140 article-title: Overexpression of tissue factor induced atherothrombosis in apolipoprotein E-/- mice via both enhanced plaque thrombogenicity and plaque instability publication-title: J. Mol. Cell. Cardiol. – volume: 143 start-page: 45 year: 2021 end-page: 61 ident: b0060 article-title: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36 publication-title: Circulation – volume: 374 start-page: 341 year: 2008 end-page: 344 ident: b0130 article-title: Inflammation stimulates the expression of PCSK9 publication-title: Biochem. Biophys. Res. Commun. – volume: 118 start-page: 620 year: 2016 end-page: 636 ident: b0120 article-title: Endothelial cell dysfunction and the pathobiology of atherosclerosis publication-title: Circ. Res. – volume: 73 start-page: 924 year: 2021 end-page: 967 ident: b0010 article-title: Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies publication-title: Pharmacol. Rev. – volume: 130 start-page: 403 year: 2012 end-page: 408 ident: b0145 article-title: The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle publication-title: Thromb. Res. – volume: 32 start-page: 150 year: 2011 end-page: 157 ident: b0030 article-title: Comparison of ruptured coronary plaques in patients with unstable and stable clinical presentation publication-title: J. Thromb. Thrombolysis – volume: 22 year: 2021 ident: b0110 article-title: PCSK9 induces tissue factor expression by activation of TLR4/NFkB signaling publication-title: Int. J. Mol. Sci. – volume: 2 start-page: e1911130 year: 2019 ident: 10.1016/j.bcp.2024.116314_b0075 article-title: A genetic approach to the association between PCSK9 and sepsis publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.11130 – volume: 129 start-page: 1167 year: 2019 ident: 10.1016/j.bcp.2024.116314_b0090 article-title: c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow publication-title: J. Clin. Invest. doi: 10.1172/JCI122440 – volume: 118 start-page: 620 year: 2016 ident: 10.1016/j.bcp.2024.116314_b0120 article-title: Endothelial cell dysfunction and the pathobiology of atherosclerosis publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.115.306301 – volume: 13 year: 2022 ident: 10.1016/j.bcp.2024.116314_b0095 article-title: Targeting PCSK9 ameliorates graft vascular disease in mice by inhibiting NLRP3 inflammasome activation in vascular smooth muscle cells publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.894789 – volume: 21 start-page: 273 year: 2022 ident: 10.1016/j.bcp.2024.116314_b0005 article-title: Management of atherosclerotic extracranial carotid artery stenosis publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(21)00359-8 – volume: 17 start-page: 52 year: 2020 ident: 10.1016/j.bcp.2024.116314_b0015 article-title: Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-019-0239-5 – volume: 113 start-page: 722 year: 2006 ident: 10.1016/j.bcp.2024.116314_b0025 article-title: Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.567297 – volume: 13 start-page: 312 year: 2016 ident: 10.1016/j.bcp.2024.116314_b0135 article-title: Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus publication-title: J. Geriatr. Cardiol. – volume: 116 start-page: 908 year: 2020 ident: 10.1016/j.bcp.2024.116314_b0080 article-title: PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1 publication-title: Cardiovasc. Res. doi: 10.1093/cvr/cvz313 – volume: 113 start-page: 363 year: 2015 ident: 10.1016/j.bcp.2024.116314_b0045 article-title: The adipokine apelin-13 induces expression of prothrombotic tissue factor publication-title: Thromb. Haemost. doi: 10.1160/TH14-05-0451 – volume: 13 start-page: 2914 year: 2023 ident: 10.1016/j.bcp.2024.116314_b0070 article-title: PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging publication-title: Theranostics doi: 10.7150/thno.83914 – volume: 20 year: 2019 ident: 10.1016/j.bcp.2024.116314_b0155 article-title: Peach kernel oil downregulates expression of tissue factor and reduces atherosclerosis in ApoE knockout Mice publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20020405 – volume: 127 start-page: 1 year: 2019 ident: 10.1016/j.bcp.2024.116314_b0140 article-title: Overexpression of tissue factor induced atherothrombosis in apolipoprotein E-/- mice via both enhanced plaque thrombogenicity and plaque instability publication-title: J. Mol. Cell. Cardiol. doi: 10.1016/j.yjmcc.2018.11.018 – volume: 101 start-page: 2651 year: 2000 ident: 10.1016/j.bcp.2024.116314_b0050 article-title: Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis publication-title: Circulation doi: 10.1161/01.CIR.101.22.2651 – volume: 38 start-page: 709 year: 2018 ident: 10.1016/j.bcp.2024.116314_b0020 article-title: Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.117.309846 – volume: 32 start-page: 150 year: 2011 ident: 10.1016/j.bcp.2024.116314_b0030 article-title: Comparison of ruptured coronary plaques in patients with unstable and stable clinical presentation publication-title: J. Thromb. Thrombolysis doi: 10.1007/s11239-011-0585-6 – volume: 22 year: 2021 ident: 10.1016/j.bcp.2024.116314_b0110 article-title: PCSK9 induces tissue factor expression by activation of TLR4/NFkB signaling publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms222312640 – volume: 374 start-page: 341 year: 2008 ident: 10.1016/j.bcp.2024.116314_b0130 article-title: Inflammation stimulates the expression of PCSK9 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2008.07.023 – volume: 91 start-page: 619 year: 1995 ident: 10.1016/j.bcp.2024.116314_b0035 article-title: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes publication-title: Circulation doi: 10.1161/01.CIR.91.3.619 – volume: 9 year: 2022 ident: 10.1016/j.bcp.2024.116314_b0115 article-title: The endothelium as a hub for cellular communication in atherogenesis: is there directionality to the message? publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2022.888390 – volume: 15 start-page: 52 year: 2018 ident: 10.1016/j.bcp.2024.116314_b0055 article-title: Inhibiting PCSK9 - biology beyond LDL control publication-title: Nat. Rev. Endocrinol. doi: 10.1038/s41574-018-0110-5 – volume: 885 year: 2020 ident: 10.1016/j.bcp.2024.116314_b0040 article-title: Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-kappaB pathway publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2020.173422 – volume: 143 start-page: 45 year: 2021 ident: 10.1016/j.bcp.2024.116314_b0060 article-title: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.046290 – volume: 130 start-page: 403 year: 2012 ident: 10.1016/j.bcp.2024.116314_b0145 article-title: The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle publication-title: Thromb. Res. doi: 10.1016/j.thromres.2012.06.007 – volume: 73 start-page: 924 year: 2021 ident: 10.1016/j.bcp.2024.116314_b0010 article-title: Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies publication-title: Pharmacol. Rev. doi: 10.1124/pharmrev.120.000096 – volume: 126 year: 2024 ident: 10.1016/j.bcp.2024.116314_b0105 article-title: PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2023.111195 – volume: 43 start-page: 558 year: 2022 ident: 10.1016/j.bcp.2024.116314_b0065 article-title: The Multifaceted Biology of PCSK9 publication-title: Endocr. Rev. doi: 10.1210/endrev/bnab035 – volume: 145 start-page: 675 year: 2022 ident: 10.1016/j.bcp.2024.116314_b0100 article-title: Ablation of plasma prekallikrein decreases low-density lipoprotein cholesterol by stabilizing low-density lipoprotein receptor and protects against atherosclerosis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.056491 – volume: 262 start-page: 113 year: 2017 ident: 10.1016/j.bcp.2024.116314_b0085 article-title: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2017.04.023 – volume: 105 start-page: 1756 year: 2002 ident: 10.1016/j.bcp.2024.116314_b0150 article-title: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways publication-title: Circulation doi: 10.1161/01.CIR.0000015465.73933.3B – volume: 11 start-page: e023328 year: 2022 ident: 10.1016/j.bcp.2024.116314_b0125 article-title: Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.121.023328 |
SSID | ssj0006861 |
Score | 2.4682739 |
Snippet | [Display omitted]
Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play... Atherosclerosis, a chronic inflammatory disease, is the most relevant cause of carotid artery stenosis. Vascular endothelial cells (ECs) play a significant... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 116314 |
SubjectTerms | Animals Apolipoproteins E - deficiency Apolipoproteins E - genetics Apolipoproteins E - metabolism Atherosclerosis Carotid artery stenosis Carotid Stenosis - metabolism Endothelial cells Endothelial Cells - drug effects Endothelial Cells - metabolism Female Human Umbilical Vein Endothelial Cells - metabolism Humans Male Mice Mice, Inbred C57BL Mice, Knockout Mice, Knockout, ApoE NF-kappa B - metabolism PCSK9 Inhibitors Proprotein Convertase 9 - genetics Proprotein Convertase 9 - metabolism Proprotein convertase subtilisin/kexin type 9 Signal Transduction - physiology Thromboplastin - biosynthesis Thromboplastin - genetics Thromboplastin - metabolism Tissue factor Toll-Like Receptor 4 - genetics Toll-Like Receptor 4 - metabolism |
Title | PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway |
URI | https://dx.doi.org/10.1016/j.bcp.2024.116314 https://www.ncbi.nlm.nih.gov/pubmed/38797271 https://www.proquest.com/docview/3060752489 |
Volume | 225 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELbK9gAXBOWny081SKgHVLNZ23Hi47LqaqFotYKt1FvkxE4VVCUrNm3JhdfgXXgInolx4mzFoT1wTJRRLI8981n-Zj5C3mJOzVgkBWUyVFRobqkWMqRcxO7WKFIma1m-Czk_FZ_OwrMdMu1rYRyt0sf-Lqa30dq_GfnZHK2LwtX4BpKpsGVBMuXqyHcZVzIckN3Jx5P5YhuQZSy9cJ6kzqC_3GxpXmnmulYygbFD8rG4LT3dBj_bNDR7RB56_AiTboiPyY4t98j9aS_btkcOl10z6uYIVje1VZsjOITlTZvq5gn5tZx-PVGgz50CESJOA07Cpy4MtDTPBtD_ZbUpNlCUMFlXx3REwYnXQ9rAumPxleeAABLsD0-nLaHKoW59CV7Jx1nb0rhCrwtc6-BuCjZwVejWcvX5ixgtZvTP7w_gxJGvdfOUnM6OV9M59TINNGMyrmkWhIFmMpJ5lBrMbnnMbaRVGONJillpeIqgSMd5GujM5JzlsbEaA6XJXB2vCfgzMiir0u4TiCzCj9iqwGZSGK3T0CoR8TyVKZ6LuBmSoPdOkvke5k5K4yLpyWrfEnRo4hyadA4dkndbk3XXwOOuj0Xv8uSfVZhggrnL7E2_PBL0tptIXdrqcpPggQwxGROxGpLn3brZjoLjTkD0OH7xfz99SR64p446_IoM6u-X9jUCpDo9IPfe_xwf-G3wF9EHDnk |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqcigXBOVvKT-DhHpANZvajpMcy6qrhS6rFWyl3iw7dqqgKlmRtJALr8G78BA8E-P8dMWhPXBNYsXyjGc-y9_MR8gbzKkpi6SgTIYJFZo7qoUMKRexvzWKEpu2LN-FnJ2Kj2fh2RaZDLUwnlbZx_4uprfRun8y7ldzvM5zX-MbSJaELQuSJb6O_I4IeeR5fe9-bngeMpa9bJ6k_vPharMleZnU96xkAiOH5IfipuR0E_hsk9D0PrnXo0c46ib4gGy5YpfsTAbRtl2yv-xaUTcHsNpUVlUHsA_LTZPq5iH5tZx8OUlAn3v9IcSbFryAT51baEmeDaD1i7LKK8gLOFqXx3RMwUvXg2lg3XH4inNA-AjuR0-mLaDMoG4tCb2Ojx_tCuvLvC7Q08HfE1Rwlet25Gr-WYwXU_rn93vw0sjfdfOInE6PV5MZ7UUaaMpkXNM0CAPNZCSzyFjMbVnMXaSTMMZzFHPScoOQSMeZCXRqM86y2DqNYdKmvorXBvwx2S7Kwj0lEDkEH7FLApdKYbU2oUtExDMjDZ6KuB2RYLCOSvsO5l5I40INVLWvCg2qvEFVZ9AReXs9ZN2177jtYzGYXP3jgwrTy23DXg_uodDafiF14crLSuFxDBEZE3EyIk86v7meBcd9gNjx8Nn__fQV2ZmtPs3V_MPiZI_c9W86EvFzsl1_u3QvECrV5mW7Ff4CHjAPRA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PCSK9+aggravated+carotid+artery+stenosis+in+ApoE-%2F-+mice+by+promoting+the+expression+of+tissue+factors+in+endothelial+cells+via+the+TLR4%2FNF-%CE%BAB+pathway&rft.jtitle=Biochemical+pharmacology&rft.au=Peng%2C+Chao&rft.au=Li%2C+Jian&rft.au=Chen%2C+Yan&rft.au=Zhang%2C+Heng-rui&rft.date=2024-07-01&rft.issn=0006-2952&rft.volume=225&rft.spage=116314&rft_id=info:doi/10.1016%2Fj.bcp.2024.116314&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bcp_2024_116314 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2952&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2952&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2952&client=summon |